The New Jersey Innovation Institute has launched a training program for biopharmaceutical companies to study new immunotherapies, such as CAR-T cell therapy.
Immunotherapy generally is a treatment in which cells in the human body are recoded and injected back into a patient in order to train the patient’s immune system to fight various diseases such as cancer. Cancer centers such as Hackensack Meridian Health’s John Theurer Cancer Center and Memorial Sloan Kettering, and pharmaceutical giants including Celgene and Johnson & Johnson have made big bets on the treatment.
The workforce training program is in response to increasing demands from the biopharmaceutical industry for engineers and scientists to be trained in manufacturing and processing of the newest breakthroughs in biologic and immunotherapies such as advanced CAR-T therapy.
The program will combine lectures and hands-on training to introduce the newest approaches and technologies applied to the development and production of these innovative therapies.
“The pharmaceutical industry faces formidable challenges as it adapts to the new culture of biotechnology,” said NJII CEO Donald Sebastian, during NJII’s Annual Innovation Summit in Newark on March 15. “This training initiative demonstrates NJII’s commitment to advance cell and gene therapy manufacturing and processing innovation.”